research: disappointing results: iniparib, PARP inhibitor

Recently, I reported on the positive results of iniparib, a PARP inhibitor, for treating metastatic triple-negative breast cancer. Sadly, further investigation has reported results that iniparib fails to extend survival at a statistically significant rate even though it extends overall survival by five months. The investigators will report the data at upcoming national and international conferences of clinical oncologists.

5 6 7 8
© 2004–2011 Donna Peach. All rights reserved.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s